Johnson & Johnson Wins FDA Nod for RYBREVANT FASPRO
New Brunswick, New Jersey, USA November 5, 2026 Johnson & Johnson (J&J) has announced that the U.S. Food and...
eGFR
Advertisement
HUTCHMED Initiates Global Phase I Trial of HMPL-A830
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 28, 2026 HUTCHMED (China) Limited announced the initiation of the...
Genentech Reports Positive Interim Phase 3 Sefaxersen Data
SOUTH SAN FRANCISCO, Calif. — September 22, 2026 Genentech reported positive prespecified interim results from the ongoing Phase 3...
Roche Reports Positive Phase 3 Sefaxersen Data in IgAN
BASEL, Switzerland — September 23, 2026 Roche announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study...
A2 Biotherapeutics Advances A2B395 in Solid Tumors
AGOURA HILLS, Calif. — September 15, 2026 A2 Biotherapeutics announced encouraging early safety and efficacy findings from the ongoing...
Advertisements
Vera Therapeutics TRUTAKNA Shows Two-Year Kidney Benefit
Brisbane, California, USA, September 15, 2026 Vera Therapeutics has announced final efficacy results from the Phase 3 ORIGIN 3...
Otsuka Advances VOYXACT with Landmark Two-Year Phase 3 IgAN Results
TOKYO, Japan, August 4, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. announced new two-year...
Replimune’s RP1 Gains FDA Panel Support for Advanced Melanoma
WOBURN, Mass., July 30, 2026 Replimune Group, Inc. announced a favorable outcome from the U.S. Food and Drug Administration’s...
Hansoh Pharma’s Ris-Rez Succeeds in Phase 3 Osteosarcoma Trial
SHANGHAI, July 28, 2026 Hansoh Pharmaceutical Group Co., Ltd. announced that risvutatug rezetecan (Ris-Rez/HS-20093), its proprietary B7-H3-directed antibody-drug conjugate...
FibroBiologics Advances CYWC628 Phase 1/2 Wound Trial
HOUSTON, July 31, 2026 FibroBiologics, Inc. has begun dosing patients in its Phase 1/2 clinical trial evaluating CYWC628, a...
Advertisement
